

# ANTICANCER RESEARCH

## International Journal of Cancer Research and Treatment

ISSN: 0250-7005

Volume 38, Number 1, January 2018

### Contents

#### Reviews

Cancer Progenitor Cells: The Result of an Epigenetic Event? K. LAPINSKA, G. FARIA, S. MCGONAGLE, K.M. MACUMBER, S. HEERBOTH, S. SARKAR ( <i>North Haven, CT; Wellesley; Quincy; Boston, MA; Nashville, TN, USA</i> ).....	1
The Role of Prophylactic Cranial Irradiation for Non-small Cell Lung Cancer. C. PRECIVAL, M. LANDY, C. POOLE, L. MULLANEY ( <i>Dublin, Ireland</i> ).....	7
Regimens of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. K. MURONO, K. KAWAI, K. HATA, S. EMOTO, M. KANEKO, K. SASAKI, T. NISHIKAWA, K. OTANI, T. TANAKA, H. NOZAWA ( <i>Tokyo, Japan</i> ).....	15
Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review. P. JARDEL, S. VIGNOT, B. CUTULI, A. CREISSON, S. VASS, E. BARRANGER, J. THARIAT ( <i>Saguenay, QC, Canada; Le Coudray; Reims; Nice; Caen, France</i> ).....	23
Managing Focal Nodular Hyperplasia of the Liver: Surgery or Minimally-invasive Approaches? A Review of the Preferable Treatment Options. E. VIRGILIO, M. CAVALLINI ( <i>Rome, Italy</i> ).....	33
Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect? C. DAMASKOS, I. TOMOS, N. GARMPI, A. KARAKATSANI, D. DIMITROULIS, A. GARMPI, E. SPARTALIS, C.F. KAMPOLIS, E. TSAGKARI, A.A. LOUKERI, G.-A. MARGONIS, M. SPARTALIS, N. ANDREATOS, D. SCHIZAS, S. KOKKINELI, E.A. ANTONIOU, A. NONNI, G. TSOUROUFLIS, K. MARKATOS, K. KONTZOGLU, A. KOSTAKIS, P. TOMOS ( <i>Athens, Greece; Baltimore, ML, USA</i> ).....	37

Contents continued on the back cover

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment



ISSN (print): 0250-7005  
ISSN (online): 1791-7530

## Editorial Board

- P. A. ABRAHAMSSON, Malmö, Sweden  
B. B. AGGARWAL, Houston, TX, USA  
T. AKIMOTO, Kashiwa, Chiba, Japan  
P. Z. ANASTASIADIS, Jacksonville, FL, USA  
A. ARGIRIS, San Antonio, TX, USA  
J. P. ARMAND, Toulouse, France  
V. I. AVRAMIS, Los Angeles, CA, USA  
D.-T. BAU, Taichung, Taiwan, ROC  
G. BAUER, Freiburg, Germany  
E. E. BAULIEU, Le Kremlin-Bicetre, France  
E. J. BENZ, Jr., Boston, MA, USA  
J. BERGH, Stockholm, Sweden  
F. T. BOSMAN, Lausanne, Switzerland  
M. BOUVET, La Jolla, CA, USA  
J. BOYD, Miami, FL, USA  
G. BROICH, Monza, Italy  
Ø. S. BRULAND, Oslo, Norway  
J. M. BUATTI, Iowa City, IA, USA  
M. M. BURGER, Basel, Switzerland  
M. CARBONE, Honolulu, HI, USA  
C. CARLBERG, Kuopio, Finland  
J. CARLSSON, Uppsala, Sweden  
A. F. CHAMBERS, London, ON, Canada  
P. CHANDRA, Frankfurt am Main, Germany  
L. CHENG, Indianapolis, IN, USA  
J.-G. CHUNG, Taichung, Taiwan, ROC  
R. CLARKE, Washington, DC, USA  
E. DE CLERCQ, Leuven, Belgium  
W. DEN OTTER, Amsterdam, The Netherlands  
E. P. DIAMANDIS, Toronto, ON, Canada  
G. TH. DIAMANDOPOULOS, Boston, MA, USA  
L. EGEVAD, Stockholm, Sweden  
D. W. FELSHER, Stanford, CA, USA  
J. A. FERNANDEZ-POL, Chesterfield, MO, USA  
I. J. FIDLER, Houston, TX, USA  
A. P. FIELDS, Jacksonville, FL, USA  
H. FU, Atlanta, GA, USA  
B. FUCHS, Zurich, Switzerland  
D. FUCHS, Innsbruck, Austria  
D. FUKUMURA, Boston, MA, USA  
G. GABBIANI, Geneva, Switzerland  
R. GANAPATHI, Charlotte, NC, USA  
A. F. GAZDAR, Dallas, TX, USA  
J. H. GESCHWIND, Baltimore, MD, USA  
A. GIORDANO, Philadelphia, PA, USA  
G. GITSCH, Freiburg, Germany  
M. GNANT, Vienna, Austria  
R. H. GOLDFARB, Guilford, CT, USA  
A. HELLAND, Oslo, Norway  
L. HELSON, Quakertown, PA, USA  
R. HENRIKSSON, Umeå, Sweden  
R. M. HOFFMAN, San Diego, CA, USA  
S. C. JHANWAR, New York, NY, USA  
J. V. JOHANNESSEN, Oslo, Norway  
R. JONES, London, UK  
B. KAINA, Mainz, Germany  
P. -L. KELLOKUMPU-LEHTINEN, Tampere, Finland  
D. G. KIEBACK, Schleswig, Germany  
R. KLAPDOR, Hamburg, Germany
- H. KOBAYASHI, Bethesda, MD, USA  
S. D. KOTTARIDIS, Athens, Greece  
G. R. F. KRUEGER, Köln, Germany  
Pat M. KUMAR, Manchester, UK  
Shant KUMAR, Manchester, UK  
O. D. LAERUM, Bergen, Norway  
F. J. LEJEUNE, Lausanne, Switzerland  
S. LINDER, Linköping, Sweden  
L. F. LIU, Piscataway, NJ, USA  
D. M. LOPEZ, Miami, FL, USA  
E. LUNDGREN, Umeå, Sweden  
Y. MAEHARA, Fukuoka, Japan  
J. MAHER, London, UK  
J. MARESCAUX, Strasbourg, France  
J. MARK, Skövde, Sweden  
S. S. MARTIN, Baltimore, MD, USA  
S. MITRA, Houston, TX, USA  
S. MIYAMOTO, Fukuoka, Japan  
S. MONCADA, Manchester, UK  
M. MUELLER, Villingen-Schwenningen, Germany  
F. M. MUGGIA, New York, NY, USA  
M. NAMIKI, Kanazawa, Ishikawa, Japan  
R. NARAYANAN, Boca Raton, FL, USA  
K. NILSSON, Uppsala, Sweden  
S. PATHAK, Houston, TX, USA  
J.L. PERSSON, Malmö, Sweden  
G. J. PILKINGTON, Portsmouth, UK  
C. D. PLATSOUKAS, Norfolk, VA, USA  
A. POLLIACK, Jerusalem, Israel  
D. RADES, Lübeck, Germany  
M. RIGAUD, Limoges, France  
U. RINGBORG, Stockholm, Sweden  
M. ROSELLI, Rome, Italy  
S.T. ROSEN, Duarte, CA, USA  
A. SCHAUER, Göttingen, Germany  
M. SCHNEIDER, Wuppertal, Germany  
J. SEHOULI, Berlin, Germany  
A. SETH, Toronto, ON, Canada  
G. V. SHERBET, Newcastle-upon-Tyne, UK  
A. SLOMINSKI, Birmingham, AL, USA  
G.-I. SOMA, Kagawa, Japan  
G. S. STEIN, Burlington, VT, USA  
T. STIGBRAND, Umeå, Sweden  
T. M. THEOPHANIDES, Athens, Greece  
P. M. UELAND, Bergen, Norway  
H. VAN VLIERBERGHE, Ghent, Belgium  
R. G. VILE, Rochester, MN, USA  
M. WELLER, Zurich, Switzerland  
J. WESTERMARCK, Turku, Finland  
B. WESTERMARK, Uppsala, Sweden  
Y. YEN, Duarte, CA, USA  
M.R.I. YOUNG, Charleston, SC, USA  
B. ZUMOFF, New York, NY, USA
- G. J. DELINASIOS, Athens, Greece  
Managing Editor and  
Executive Publisher
- J. G. DELINASIOS, Athens, Greece  
Managing Editor (1981-2016)

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

**U.S. Branch:** Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

E-mails: Editorial Office: journals@iia-anticancer.org

Managing Editor: editor@iia-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research. The IIAR is a member of UICC. For more information about ANTICANCER RESEARCH, IIAR and the Conferences, please visit the IIAR website: [www.iia-anticancer.org](http://www.iia-anticancer.org)

**Publication Data:** ANTICANCER RESEARCH (AR) is published bimonthly from January 1981 to December 2008 and monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

**Copyright:** On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

**Annual Subscription Rates 2018 per volume:** Institutional subscription US\$ 1,898.00 (online) or US\$ 2,277.00 (print & online). Personal subscription US\$ 897.00 (online) or US\$ 1,277.00 (print & online). Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-37, 1981-2017) are available at 50% discount on the above rates.

**Subscription Orders:** Orders can be placed at agencies, bookstores, or directly with the Publisher. (e-mail: [subscriptions@iia-anticancer.org](mailto:subscriptions@iia-anticancer.org))

**Advertising:** All correspondence and rate requests should be addressed to the Editorial Office.

**Book Reviews:** Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Obtaining permission to reuse or reproduce our content: AR has partnered with Copyright Clearance Center (CCC) to make it easy to secure permissions to reuse its content. Please visit [www.copyright.com](http://www.copyright.com) and enter the title that you are requesting permission for in the 'Get Permission' search box. For assistance in placing a permission request, Copyright Clearance Center can be contacted directly at: Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. Phone: +1-978-750-8400. Fax: +1-978-646-8600. E-mail: [info@copyright.com](mailto:info@copyright.com).

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios). All rights reserved.

D.T.P. BY IIAR

PRINTED BY ENTYP0, ATHENS, GREECE. PRINTED ON ACID-FREE PAPER

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN (print): 0250-7005, ISSN (online): 1791-7530

VOLUME 38

2018

## Editorial Board

<b>P. A. Abrahamsson</b>	Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden
<b>B. B. Aggarwal</b>	Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
<b>T. Akimoto</b>	Division of Particle Therapy and Department of Radiation Oncology, National Cancer Center East, Kashiwa, Chiba, Japan
<b>P. Z. Anastasiadis</b>	Department of Cancer Biology, Mayo Cancer Center, Jacksonville, FL, USA
<b>A. Argiris</b>	Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA
<b>J. P. Armand</b>	Institut Claudius Regaud, Toulouse, France
<b>V. I. Avramis</b>	Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
<b>D.-T. Bau</b>	Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC
<b>G. Bauer</b>	Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany
<b>E. E. Baulieu</b>	INSERM U488 and College de France, Le Kremlin-Bicetre, France
<b>E. J. Benz, Jr.</b>	Dana-Farber Cancer Institute, Boston, MA, USA
<b>J. Bergh</b>	Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
<b>F. T. Bosman</b>	Institute of Pathology, University of Lausanne, Switzerland
<b>M. Bouvet</b>	Department of Surgery, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA
<b>J. Boyd</b>	Department of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
<b>G. Broich</b>	Gruppo Policlinico di Monza, Monza, Italy
<b>Ø. S. Bruland</b>	Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
<b>J. M. Buatti</b>	Department of Radiation Oncology, University of Iowa, Iowa City, IA, USA
<b>M. M. Burger</b>	Novartis, Basel, Switzerland
<b>M. Carbone</b>	Cancer Research Center of Hawaii, Honolulu, HI, USA
<b>C. Carlberg</b>	Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
<b>J. Carlsson</b>	Department of Biomedical Radiation Sciences, Uppsala University, Sweden
<b>A. F. Chambers</b>	Department of Oncology, London Regional Cancer Center, London, Ontario, Canada
<b>P. Chandra</b>	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
<b>L. Cheng</b>	Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
<b>J.-G. Chung</b>	Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC
<b>R. Clarke</b>	Georgetown University Medical Center, Washington, DC, USA
<b>E. De Clercq</b>	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
<b>W. Den Otter</b>	VUMC, Department of Urology, Amsterdam, The Netherlands
<b>E. P. Diamandis</b>	Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
<b>G. Th. Diamandopoulos</b>	Department of Pathology, Harvard Medical School, Boston, MA, USA
<b>L. Egevad</b>	Department of Pathology, Karolinska University Hospital, Stockholm, Sweden
<b>D. W. Felsher</b>	Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
<b>J. A. Fernandez-Pol</b>	Metalloproteomics, LLC, Chesterfield, MO, USA
<b>I. J. Fidler</b>	Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
<b>A. P. Fields</b>	Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA
<b>H. Fu</b>	Discovery and Developmental Therapeutics Program of Winship Cancer Institute, Emory University, Atlanta, GA, USA
<b>B. Fuchs</b>	Balgrist University Hospital, Zurich, Switzerland
<b>D. Fuchs</b>	Center for Chemistry and Biomedicine, Innsbruck Medical University, Innsbruck, Austria

<b>D. Fukumura</b>	Edwin L. Steele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA
<b>G. Gabbiani</b>	Department of Pathology, University of Geneva, Switzerland
<b>R. Ganapathi</b>	Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
<b>A. F. Gazdar</b>	Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA
<b>J. H. Geschwind</b>	Interventional Radiology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
<b>A. Giordano</b>	Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
<b>G. Gitsch</b>	Department of Gynecology and Obstetrics, University of Freiburg, Germany
<b>M. Gnant</b>	Department of Surgery, Medical University of Vienna, Austria
<b>R. H. Goldfarb</b>	R. H. Goldfarb Sopherion Therapeutics, LLC and Translational Oncology and ImmunoEngineering Consulting, Guilford, CT, USA
<b>A. Helland</b>	Oslo University Hospital-Radium Hospital, Oslo, Norway
<b>L. Helson</b>	Sign Path Pharma, Inc., Quakertown, PA, USA
<b>R. Henriksson</b>	Department of Experimental Oncology, Umeå University, Umeå, Sweden
<b>R. M. Hoffman</b>	Department of Surgery, University of California, San Diego, CA, USA
<b>S. C. Jhanwar</b>	Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
<b>J. V. Johannessen</b>	Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
<b>R. Jones</b>	Sarcoma Unit, Royal Marsden Hospital, London, UK
<b>B. Kaina</b>	Institute of Toxicology, University of Mainz, Germany
<b>P. -L. Kellokumpu-Lehtinen</b>	Department of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland
<b>D. G. Kieback</b>	Helios Medical Center Schleswig, Schleswig, Germany
<b>R. Klapdor</b>	Medical Clinic, University of Hamburg, Germany
<b>H. Kobayashi</b>	Laboratory of Molecular Theranostics, NCI/NIH, Bethesda, MD, USA
<b>S. D. Kottaridis</b>	Department of Virology, Hellenic Anticancer Institute, Athens, Greece
<b>G. R. F. Krueger</b>	Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
<b>Pat M. Kumar</b>	Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK
<b>Shant Kumar</b>	Department Pathology, University of Manchester Medical School, Manchester, UK
<b>O. D. Laerum</b>	Department of Pathology, The Gade Institute, University of Bergen, Norway
<b>F. J. Lejeune</b>	Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
<b>S. Linder</b>	Department of Medicine and Health, Linköping University, Linköping, Sweden
<b>L. F. Liu</b>	Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA
<b>D. M. Lopez</b>	Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
<b>E. Lundgren</b>	Unit of Applied Cell and Molecular Biology, University of Umeå, Sweden
<b>Y. Maehara</b>	Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
<b>J. Maher</b>	Department of Research Oncology, Division of Cancer Studies, King's College London School of Medicine, Guy's Hospital Campus, London, UK
<b>J. Marescaux</b>	IRCAD, University of Strasbourg, France
<b>J. Mark</b>	Department of Pathology, Kärnshuset, Skövde, Sweden
<b>S. S. Martin</b>	Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, USA
<b>S. Mitra</b>	The Methodist Hospital Research Institute (TMHRI), Houston, TX, USA
<b>S. Miyamoto</b>	Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
<b>S. Moncada</b>	Manchester Cancer Research Centre, University of Manchester, Manchester, UK
<b>M. Mueller</b>	Hochschule Furtwangen University, Villingen-Schwenningen, Germany
<b>F. M. Muggia</b>	New York University Cancer Institute, School of Medicine, NY, USA

- M. Namiki** Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa City, Ishikawa, Japan
- R. Narayanan** Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
- K. Nilsson** Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden
- S. Pathak** Department of Cell Biology, University of Texas, Houston, TX, USA
- J. L. Persson** Section for Experimental Cancer Research, Clinical Research Center, Lund University, Malmö, Sweden
- G. J. Pilkington** Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK
- C. D. Platsoucas** College of Sciences, Old Dominion University, Norfolk, VA, USA
- A. Polliack** Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
- D. Rades** Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
- M. Rigaud** Laboratory Biochimie et Génétique Molécules, Faculté de Médecine de Limoges, France
- U. Ringborg** Department of General Oncology, Karolinska Hospital, Stockholm, Sweden
- M. Roselli** Department of Medical Oncology, University of Rome "Tor Vergata", Italy
- S.T. Rosen** Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA
- A. Schauer** Zentrum Pathologie, Georg-August Universität, Göttingen, Germany
- M. Schneider** Department of Organic Chemistry, Bergische University, Wuppertal, Germany
- J. Sehouli** Department of Gynecology, Center for Oncological Surgery, Charité Comprehensive Cancer Center, Berlin, Germany
- A. Seth** Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada
- G. V. Sherbet** Cancer Research Unit, University of Newcastle-upon-Tyne, UK
- A. Slominski** Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA
- G.-I. Soma** Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, Kagawa, Japan
- G. S. Stein** Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA
- T. Stigbrand** Department of Immunology, Umeå University, Umeå, Sweden
- T. M. Theophanides** Department of Chemistry, Technical University of Athens, Greece
- P. M. Ueland** Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Norway
- H. Van Vlierberghe** Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
- R.G. Vile** Department of Immunology, Mayo Clinic, Rochester, MN, USA
- M. Weller** Department of Neurology, University Hospital Zurich, Zurich, Switzerland
- J. Westermarck** Centre for Biotechnology, University of Turku, Turku, Finland
- B. Westermarck** Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden
- Y. Yen** Department of Molecular Pharmacology, City of Hope, Duarte, CA, USA
- M. R. I. Young** Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA
- B. Zumoff** Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA

## Acknowledgements

The IAR appreciates the support of the following Foundations, Institutions, Organizations and Universities for the works published in Anticancer Research, Volume 37, 2017.

- Academic Enrichment Fund (AEF), Massachusetts General Hospital (MGH), Boston, MA, U.S.A.  
 Academy of Finland, Helsinki, Finland  
 Action Lions "Vaincre le Cancer" Association, Lions Clubs, Luxembourg  
 Agence Thématique de Recherche en Sciences et Technologie (ATRST), El Harrach, Alger  
 AIL La Spezia - Sezione "Francesca Lanzone", La Spezia, Italy  
 Ajou Human Bio-Resource Bank (AHBB), Suwon, Republic of Korea  
 Albert Hung Foundation, Hong Kong, P.R. China  
 ALFA LAB Molecular Biology Center, Athens, Greece  
 Alliance Pharma Company Limited, Bangkok, Thailand  
 American Cancer Society, Atlanta, GA, U.S.A.  
 Anna University, Chennai, India  
 ARC Foundation, Vancouver, BC, Canada  
 Asan Institute for Life Sciences, Seoul, Republic of Korea  
 Asia University, Taichung, Taiwan, R.O.C.  
 Association Santelys, Loos, France  
 Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy  
 Astellas Pharma Inc., Tokyo, Japan
- Banque de tissus et de données, Réseau de recherche sur le cancer, Fonds de la recherche en santé du Québec (FRSQ), Montreal, QC, Canada  
 BANSS-Stiftung, Biedenkopf, Germany  
 Base for Human Resource Development in Nanoscience and Nanotechnology, Osaka Prefecture University, Osaka, Japan  
 Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea  
 Basic-Clinic Cooperation Project, Capital Medical University, Beijing, P.R. China  
 Baylor Scott & White Health Publication Office, Dallas, TX, U.S.A.  
 Beaumont Hospital Research Institute, Royal Oak, MI, U.S.A.  
 Beijing Health System Talents Plan Fund, Beijing, P.R. China  
 Beijing Municipal Administration of Hospitals, Beijing, P.R. China  
 Beijing Municipal Commission of Health and Family Planning, Beijing, P.R. China  
 Beijing Municipal Natural Science Foundation, Beijing, P.R. China  
 Beijing Municipal Science and Technology Commission, Beijing, P.R. China  
 Beijing Talent Training Funding, Beijing, P.R. China  
 Bergen County Academies (BCA), Hackensack, NJ, U.S.A.  
 Bert von Kantzow Foundation, Sweden  
 Biofluid Biobank, University of Bonn, Bonn, Germany  
 Biohit Oyj, Helsinki, Finland  
 Bio-oriented Technology Research Advancement Institution (BRAIN), National Agriculture and Food Research Organization (NARO), Japan  
 Biotechnology Research Program, Department of Health, Commonwealth of Pennsylvania, Harrisburg, PA, U.S.A.  
 BK21 PLUS Program for Creative Veterinary Science, Seoul National University, Seoul, Republic of Korea  
 Blood Program, Harvard Stem Cell Institute, Cambridge, MA, U.S.A.  
 Bower Foundation, Ridgeland, MS, U.S.A.  
 Breast and Endocrine Fund (ANFS), Wales, U.K.  
 Breast Cancer Hope Charity Fund, Wales, U.K.  
 Breast Cancer Hope Foundation, London, U.K.  
 Breast Cancer Society of Canada, Sarnia, ON, Canada  
 BRIC Grant, Université Libre de Bruxelles, Bruxelles, Belgium  
 Bridge Funding, Department of Surgery, Dalhousie University, Halifax, NS, Canada  
 Bristol-Myers Squibb Co., Ltd, New York, NY, U.S.A.  
 Buddhist Tzu Chi General Hospital, Hualien City, Taiwan
- Canadian Anesthesia Research Foundation (CARF), Toronto, ON, Canada  
 Canadian Breast Cancer Foundation (CBCF), Toronto, ON, Canada  
 Canadian Cancer Society Capacity Development, Toronto, ON, Canada  
 Canadian Institute of Health Research, Ottawa, ON, Canada  
 Canadian Tumour Repository Network (CTRNet), Canada  
 Cancer and Allergy Foundation, Gothenburg, Sweden  
 Cancer Research Foundation in Northern Sweden, Umeå, Sweden  
 Cancer Research Fund, Fukuoka Foundation for Sound Health, Fukuoka, Japan  
 Cancer Research Wales, Wales, U.K.

- Cancer Society of Finland, Helsinki, Finland  
Cancer Society of New Zealand, Wellington, New Zealand  
Capital Medical University, Beijing, P.R. China  
Cardiff China Medical Research Collaborative, Cardiff, U.K.  
Cardiff University China Medical Scholarship, Cardiff, U.K.  
Cardiff University–Peking University Cancer Institute, Cardiff, U.K.  
Cell Innovator, Fukuoka, Japan  
Center for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan  
Center for Cancer Research, Republic of Korea  
Center for Development and Commercialization of Anti-Cancer Therapeutics, Ministry of Health and Welfare, Seoul, Republic of Korea  
Center for Translational Cancer Research, University of Delaware, Newark, DE, U.S.A.  
Center of Innovation Program (COI), Japan Science and Technology Agency (JST), Kawaguchi, Japan  
Center of Life Science, Hiroshima University, Higashi, Hiroshima, Japan  
Central Research Institute, Fukuoka University, Fukuoka, Japan  
Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Lodz, Poland  
Chair of Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland  
Challenging Exploratory Research, Japan  
Chang Gung Medical Research Council, Chang Gung University, Taoyuan, Taiwan, R.O.C.  
Chang Gung Memorial Hospital, Puzi City, Taiwan, R.O.C.  
Chang Gung University, Taoyuan, Taiwan, R.O.C.  
Changzhou Science & Technology Bureau, Changzhou, P.R. China  
Charles University in Prague, Prague, Czech Republic  
Charles University Research Fund (PROGRES), Charles University in Prague, Prague, Czech Republic  
China International Medical Foundation (CIMF), P.R. China  
China Medical University Hospital, Taichung, Taiwan, R.O.C.  
China Medical University, Taichung, Taiwan, R.O.C.  
China Scholarship Council, P.R. China  
Chinese Medical Research Studentship of Cardiff University, Cardiff, U.K.  
Chosun University, Gwangju, Republic of Korea  
CHU Amiens, Amiens, France  
Chugai Pharmaceutical Co., Ltd, Tokyo, Japan  
Chula Research Scholar, Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University, Bangkok, Thailand  
Chungnam National University, Daejeon, Republic of Korea  
Clinical Key Project, Peking University Third Hospital, Beijing, P.R. China  
Clinical Medicine Research Laboratory, National Yang-Ming University Hospital, Taipei, Taiwan, R.O.C.  
Clinical Research Education and Career Development, NIMHD, NIH, Bethesda, MD, U.S.A.  
Clinical Research Launching Project, Beijing Friendship Hospital, Beijing, P.R. China  
Clinical Scholar Award, Alberta Heritage Foundation for Medical Research (AHFMR), University of Alberta, Edmonton, AB, Canada  
Clinical Special Fund, Science and Technology of Jiangsu Province, P.R. China  
Clinical Trial and Research Center of Excellence, Ministry of Health and Welfare, Taipei, Taiwan, R.O.C.  
College of Pharmacy and Pharmaceutical Sciences, Florida A & M University, Tallahassee, FL, U.S.A.  
College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A.  
Comité de la Somme, Amiens, France  
Comprehensive Support Project for Oncology Research (CSPOR), Public Health Research Foundation, Tokyo, Japan  
Conceptual Development of Research Organization, Faculty Hospital in Pilsen - FNPI, Pilsen, Czech Republic  
Conjoint Laboratory and the Flow Cytometer Room of the Department of Medical Research, Chang Gung Memorial Hospital, Chiayi, Taiwan, R.O.C.  
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasilia, Brazil  
Cooperation in Science and Technology (COST), EU RTD Framework Program, Brussels, Belgium  
Cooperative Research Program for Agriculture Science & Development, Rural Development Administration, Jeonju, Republic of Korea  
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasilia, Brazil  
Council for Science, Technology and Innovation (CSTI), Tokyo, Japan  
County of Västmanland, Sweden  
Cross-ministerial Strategic Innovation Promotion Program (SIP), Japan  
Cultivation for Major Projects and Emerging Interdisciplinary Funding Project, Sun Yat-sen University, Guangzhou, P.R. China  
Daiichi Sankyo Co., Ltd, Tokyo, Japan  
Dalim Pharmaceutical Corporation, Seoul, Republic of Korea  
De La Salle University Science Foundation, Manila, Philippines



- Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
- Department of Anesthesiology and Pain Medicine at Metaxa Hospital, Piraeus, Greece
- Department of Biology, Division of Natural and Social Sciences, Carthage College, Kenosha, WI, U.S.A.
- Department of Biotechnology, Ministry of Science and Technology, New Delhi, India
- Department of Clinical and Translational Sciences, Creighton University School of Medicine, Omaha, NE, U.S.A.
- Department of Clinical Microbiology, County Hospital Ryhov, Jönköping, Sweden
- Department of Clinical Research Center, Wakayama Medical University, Wakayama, Japan
- Department of Defense, Arlington County, VA, U.S.A.
- Department of Education, Development and Research, Hospital Center of Porto, Porto, Portugal
- Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
- Department of International Medical Communications, Tokyo Medical University, Tokyo, Japan
- Department of Interventional MRI, Shandong Medical Imaging Research Institute, Shandong University, Shandong, P.R. China
- Department of Laboratory Medicine, Lund University, Lund, Sweden
- Department of Molecular Pharmacology and Oncology, Graduate School of Medicine, Gunma University, Maebashi, Japan
- Department of Pathology and Microbiology, Saga University, Saga, Japan
- Department of Pathology and Oncology, University of Occupational and Environmental Health, Kitakyushu, Japan
- Department of Pathology, Fukuoka-Wajiro Hospital, Fukuoka, Japan
- Department of Pathology, Saitama Medical University International Medical Center, Moroyama, Japan
- Department of Pathology, Tokushima University School of Medicine, Tokushima, Japan
- Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS, U.S.A.
- Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Hyogo, Japan
- Department of Preventive Medicine, Tokai University School of Medicine, Isehara, Japan
- Department of Radiation Oncology, Froedtert Hospital, Milwaukee, WI, U.S.A.
- Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Japan
- Department of Surgery, Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan
- Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan
- Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
- Department of Veterinary Internal Medicine, University of Tokyo, Tokyo, Japan
- Departments of Oncology and Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, U.S.A.
- Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany
- Discovery Foundation, Texas A&M Health Science Center, Temple, TX, U.S.A.
- Ditmanson Medical Foundation, Chia-Yi Christian Hospital, Chiayi city, Taiwan, R.O.C.
- Diversity Grant, National Institute of Radiological Sciences (NIRS)-Chiba University, Chiba, Japan
- Division of Pneumology, San Bartolomeo Hospital, Sarzana, Italy
- Divisions of Gastroenterological Surgery and Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan
- DNA Sequencing Facility, Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
- DRG International, Inc, Springfield, NJ, U.S.A.
- Edanz Group, Fukuoka, Japan
- Een Häerz fir kriibskrank Kanner Association, Luxembourg
- Ehime Prefectural University of Health Sciences, Iyo-gun, Japan
- Eileen-Iwanicki Fellowship for Breast Cancer Research, Canadian Institutes of Health Research, Canada
- Eisai Co., Ltd., Tokyo, Japan
- Elite Young Scholars Program, Sun Yat-sen Memorial Hospital, Guangzhou, P.R. China
- Enago, Tokyo, Japan
- Enrico and Enrica Sovena Foundation, Rome, Italy
- Epigenetics Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, U.S.A.
- EP-SOGO Co., Ltd, Tokyo, Japan
- European Commission, Brussels, Belgium
- European Regional Development Fund, Brussels, Belgium
- European Social Fund (ESF), European Commission, Brussels, Belgium

- EuroTransBio (ETB), Jülich, Germany  
 EVO Funds, Helsinki University Hospital, Helsinki, Finland  
 EVO Funds, Kuopio University Hospital, Kuopio, Finland  
 Extramural Collaborative Research Grant of Cancer  
 Research Institute, Kanazawa University, Kanazawa, Japan  
 Extramural Research Facilities Program, National Center for  
 Research Resources, Bethesda, MD, U.S.A.
- Faculty Hospital in Pilsen, Pilsen, Czech Republic  
 Faculty Hospital Plzen, Plzeň, Czech Republic  
 Faculty of Medicine in Pilsen, Pilsen, Czech Republic  
 Faculty of Medicine, Khon Kaen University, Khon Kaen,  
 Thailand  
 Faculty of Pharmaceutical Sciences, Tokushima Bunri  
 University, Tokushima, Japan  
 Faculty of Science, Mahidol University, Salaya, Thailand  
 Faculty of Veterinary Medicine, Wrocław University of  
 Environmental and Life Sciences, Wrocław, Poland  
 Faculty Research Award Program Individual Investigator  
 Award, Eugene Applebaum College of Pharmacy and  
 Health Sciences, Wayne State University, Detroit, MI,  
 U.S.A.
- Ferdinand Eisenberger-Fellowship, German Society of  
 Urology, Germany  
 Finnish Cancer Foundation, Helsinki, Finland  
 Fondation contre le Cancer, Schaerbeek, Belgium  
 Fondation de Recherche Cancer et Sang, Luxembourg  
 Fondation des hôpitaux Enfant-Jésus-Saint-Sacrement,  
 Canada  
 Fondation du cancer du sein du Québec, Canada  
 Fondazione del Monte di Bologna e Ravenna, Italy  
 Fondazione Monte di Bologna and Ravenna, Bologna,  
 Italy  
 Fonds de recherche du Québec - Santé (FRQS), Canada  
 Foundation for the Promotion of Cancer Research, Tokyo,  
 Japan  
 Foundation for Young Scientists, Affiliated Hospital of  
 Jiangsu University, Jiangsu, P.R. China  
 Founding Program for Next Generation World-leading  
 Researchers, Japan  
 Fundação Amazônia Paraense do Estado do Pará  
 (FAPESPA), São Paulo, Brazil  
 Fundação de Amparo à Pesquisa do Rio Grande do Sul  
 (FAPERGS), Rio Grande do Sul, Brazil  
 Fundação para a Ciência e a Tecnologia (FCT), Ministério  
 da Ciência e Ensino Superior, Portugal  
 Project for Cancer  
 Research and Therapeutic Evolution (P-CREATE), Japan  
 Agency for Medical Research and Development (AMED),  
 Tokyo, Japan
- Gachon University Gil Medical Center, Incheon, Republic of  
 Korea  
 Garvan Institute, Sydney, Australia  
 Gattegno and Wechsler Funds, Boston, MA, U.S.A.  
 General Directorate for Scientific Research and  
 Technological Development (DGRSDT), Algiers, Algeria  
 GeneticLab Co., Ltd, Sapporo, Japan  
 Georgia Cancer Center, Augusta, GA, U.S.A.  
 German Foundation for Young Adults with Cancer, Germany  
 Golfers Against Cancer Grant, Wake Forest Baptist  
 Comprehensive Cancer Center, Winston-Salem, NC, U.S.A.  
 Government of Portugal, Portugal  
 Graduate School of Medical Sciences, Kitasato University,  
 Tokyo, Japan  
 Grants-in-Aid for Scientific Research (KAKENHI), Japan  
 Society for the Promotion of Science, Tokyo, Japan  
 Grimes Family Foundation Endowment in Gynecologic  
 Oncology, Texas A&M Health Science Center, Temple,  
 TX, U.S.A.  
 Guangzhou Science and Technology Bureau, Guangzhou,  
 P.R. China  
 Gunma University Initiative for Advanced Research (GIAR),  
 Maebashi, Japan  
 GynOp Registry, Umeå, Sweden
- H.W. & J. Hector-Stiftung, Mannheim, Germany  
 Hai Chau Centre Medical Diagnostic Center, Danang,  
 Vietnam  
 Hans Sauer Stiftung, Munich, Germany  
 Healing Leaves Clinic and Wellness Center, Makati,  
 Philippines  
 Heavy Ion Medical Center, Gunma University, Maebashi,  
 Japan  
 Heikki, Aino and Aarne Korhonen Foundation, Finland  
 Hellenic Cooperative Oncology Group, Athens, Greece  
 Hiroshima Red Cross Hospital and Atomic-bomb Survivors  
 Hospital, Hiroshima, Japan  
 HistoBio Diagnosis (HBD), Athens, Greece  
 Histology Section, Tissue Core, Moffitt Cancer Center &  
 Research Institute, Tampa, FL, U.S.A.  
 Histopathology and Cytopathology Division and Clinical  
 Pathology Division, Sant' Andrea Hospital, La Spezia,  
 Italy  
 Howard Hughes Medical Institute (HHMI), Chevy Chase,  
 MD, U.S.A.  
 Human Genome Center at the Institute of Medical Science,  
 University of Tokyo, Tokyo, Japan  
 Human Genome Center, Institute of Medical Science,  
 University of Tokyo, Tokyo, Japan

- Hungarian Brain Research Program, Hungary  
 Hyogo College of Medicine, Nishinomiya, Japan  
 Hyogo Prefecture Health Promotion Association, Hyogo, Japan  
 Hyogo Science and Technology Association, Hyogo, Japan
- Ichiro Kanehara Foundation, Tokyo, Japan  
 Iizuka Hospital, Fukuoka, Japan  
 IMEREM/RPS Clinical Research, RPS Germany, Nuremberg, Germany  
 Importation and Development of High-Caliber Talents Project of Beijing Municipal Institutions, Beijing, P.R. China  
 INCT/CNPq-Inovação Farmacêutica, Brazil  
 Industrial Strategic Technology Development Program, Ministry of Trade, Industry, & Energy (MOTIE), Sejong, Republic of Korea  
 Institute for Biomedical Science (IBS), Chonnam National University Hwasun Hospital(CNUHH), Hwasun-eup, Republic of Korea  
 Institute of Biomathematics, Faculty of Medicine, Mannheim, Germany  
 Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine in Vienna, Vienna, Austria  
 Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine, Vienna, Austria  
 Institute of Molecular Medicine, Faculty of Medicine of Lisbon, University of Lisbon, Lisbon, Portugal  
 Institute of Physiology, University Hospital Zurich, Zurich, Switzerland  
 Institutes of Shanghai Municipal Education Commission, Shanghai, P.R. China  
 Instituto Gulbenkian de Ciência, Oeiras, Portugal  
 Intramural Research Program, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, U.S.A.  
 Istanbul University Scientific Research Coordination Unit, Istanbul, Turkey  
 Italian Association for Cancer Research (AIRC), Milan, Italy  
 Italian Ministry of Health, Rome, Italy  
 Itoh-Chubei Foundation, Japan
- Jagiellonian University, Cracow, Poland  
 Jan Kochanowski University, Kielce, Poland  
 János Bolyai Scholarship, Hungarian Academy of Sciences, Budapest, Hungary  
 Japan Agency for Medical Research and Development (AMED), Tokyo, Japan
- Japan Foundation for Applied Enzymology, Osaka, Japan  
 Japan Science and Technology Agency (JST), Kawaguchi, Japan  
 Japan Society for the Promotion of Science (JSPS), Tokyo, Japan  
 Jiangsu Provincial Medical Youth Talent, Jiangsu, P.R. China  
 John Sealy Memorial Endowment Fund, University of Texas Medical Branch (UTMB), Galveston, TX, U.S.A.  
 Junior Science Talent Project (JSTP), Pathum Thani, Thailand
- Kadner-Pitts Research Grant, Loyola Marymount University, Los Angeles, CA, U.S.A.  
 Kahramanmaras Sutcu Imam University Research, Kahramanmaras, Turkey  
 Kakiyama Science and Technology Foundation, Fukuoka, Japan  
 Kanazawa Medical Research Foundation, Kanazawa, Japan  
 Kansai Genshiryoku Kondankai, Osaka, Japan  
 Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.  
 Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan, R.O.C.  
 Karolinska Institute, Stockholm, Sweden  
 Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy, Guangdong Higher Education Institutes Grant, Guangdong Science and Technology Department, Guangdong, P.R. China  
 Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine, Guangzhou Bureau of Science and Information Technology, Guangzhou, P.R. China  
 Key Research and Development Plan of Shandong Province, Shandong, P.R. China  
 Khon Kaen University, Khon Kaen, Thailand  
 King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia  
 KKU Publication Clinic, Bangkok, Khon Kaen, Thailand  
 Kochi Organization for Medical Reformation and Renewal Grants, Kochi, Japan  
 Konkuk University, Seoul, Republic of Korea  
 Korea Health Technology R&D Project, Korean Health Industry Development Institute (KHIDI), Ministry of Health & Welfare, Seoul, Republic of Korea  
 Korea Institute of Oriental Medicine, Ministry of Education, Science and Technology (MEST), Seoul, Republic of Korea  
 Korea Institute of Radiological and Medical Sciences (KIRAMS), Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea  
 Korea Research Foundation, Republic of Korea  
 Korea University Guro Hospital of National Biobank, Seoul, Republic of Korea

- KUULAS Helsinki/Business Science Helsinki, Helsinki, Finland  
 Kyoto University, Kyoto, Japan
- Laboratory for Process Engineering, Environment, Biotechnology and Energy (LEPABE), Porto, Portugal  
 Laval University Cancer Research Center, Quebec, QC, Canada  
 Leading Graduate Schools, Cultivating Global Leaders in Heavy Ion Therapeutics and Engineering, Gunma University, Maebashi, Japan  
 Leading University, Sylhet, Bangladesh  
 Les Amis de l'Institut J. Bordet, Bruxelles, Belgium  
 Leukemia Research Foundation Grant, Italy  
 Life Sciences National Research Network Wales (LSRNW/Ser Cymru), Cardiff, Wales, U.K.  
 Liga Portuguesa Contra o Cancro, Lisbon, Portugal  
 Ligue Contre le Cancer de Loire-Atlantique, Nantes, France  
 Ligue Contre le Cancer, Paris, France  
 Lions Cancerforskningsfond, Uppsala, Sweden  
 Lipidomics Shared Resource Facility, Medical University of South Carolina, Charleston, SC, U.S.A.  
 Ludwig-Maximilians-Universität München (LMU), Munich, Germany
- Madou Sin-Lau Hospital, Tainan, Taiwan, R.O.C.  
 Magnus Bergvalls Stiftelse, Stockholm, Sweden  
 Mahidol University, Salaya, Thailand  
 Management Expenses Grant, Ministry of Education, Culture, Sports, Science and Technology, Japan  
 Margarete Bonifer-Stiftung, Bad Soden, Germany  
 Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, U.S.A.  
 Masaryk University, Brno, Czech Republic  
 Medac GmbH, Wedel, Germany  
 Medical and Biological Laboratories Co., Ltd, Japan  
 Medical Faculty, University of Pécs, Pécs, Hungary  
 Medical Research Collaborating Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea  
 Medical Research Core Facilities Center, Office of Research & Development, China Medical University, Taichung, Taiwan, R.O.C.  
 Medical Research Encouragement Prize, The Japan Medical Association, Tokyo, Japan  
 Medical Scientific Research Foundation of Guangdong Province, P.R. China  
 Medical University of Bialystok, Bialystok, Poland  
 Medicine, Odontology and Health (ALF), Stockholm, Sweden
- Mediterranean Cancer Support and Rehabilitation – Medicare Onlus, Catania, Italy  
 Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan  
 Ministry of Education, Science and Technology (MEST), Seoul, Republic of Korea  
 Ministry of Education, Youth and Sports, Prague, Czech Republic  
 Ministry of Health, Prague, Czech Republic  
 Ministry of Health, Rome, Italy  
 Ministry of Science and Higher Education, Warsaw, Poland  
 Ministry of Science and Technology (MOST), Taipei, Taiwan, R.O.C.  
 Ministry of Science, Education and Sports, Zagreb, Republic of Croatia  
 Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea  
 Mochida Pharmaceutical Co., Ltd, Tokyo, Japan  
 Molecular Science Unit of Center Natural Sciences and Environmental Research (CENSER), De La Salle University, Manila, Philippines  
 Musella Foundation for Brain Tumor Research & Information, Hewlett, NY, U.S.A.
- Nagai Memorial Research Scholarship, Pharmaceutical Society of Japan, Tokyo, Japan  
 National Cancer Center Research and Development Fund, Tokyo, Japan  
 National Cancer Center, Seoul, Republic of Korea  
 National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, Bethesda, MD, U.S.A.  
 National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Department of Health and Human Services, Bethesda, MD, U.S.A.  
 National Disease Surveillance System, China Center for Disease Control and Prevention (CDC), Beijing, P.R. China  
 National Health Research Institutes, Taipei, Taiwan R.O.C.  
 National Heart Lung and Blood Institute (NHLBI), NIH, Bethesda, MD, U.S.A.  
 National Institute of General Medical Sciences (NIGMS), NIH, Bethesda, MD, U.S.A.  
 National Institute of Minority Health and Health Disparities (NIMHD), NIH, Bethesda, MD, U.S.A.  
 National Institute of Radiological Sciences (NIRS), Chiba, Japan  
 National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan

- National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, U.S.A.
- National Key Research and Development Program of China, Beijing, P.R. China
- National Kyushu Cancer Center, Kyushu, Japan
- National Natural Science Foundation of China, Guangdong, P.R. China
- National Plan Science, Technology and Innovation (MAARIFAH), King Saud University, Riyadh, Kingdom of Saudi Arabia
- National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
- National Research Foundation, Pretoria, South Africa
- National Research Program for Universities (NRPU), Higher Education Commission of Pakistan, Islamabad, Pakistan
- National Science and Technology Development Agency (NSTDA), Pathum Thani, Thailand
- National Science Center (NCN), Krakow, Poland
- National Science Centre (NCN), Warsaw, Poland
- National Science Council, Taipei, Taiwan, R.O.C.
- National Science Foundation of Guangdong Province, Guangdong, P.R. China
- National Sun Yat-sen University (NSYSU)-Kaohsiung Medical University(KMU) Joint Research Project, Kaohsiung, Taiwan, R.O.C.
- National Sustainability Program I (NPU I), Ministry of Education Youth and Sports, Prague, Czech Republic
- National Sustainability Program I (NPU I), Ministry of Education Youth and Sports of the Czech Republic, Prague, Czech Republic
- National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
- National Taiwan University Hospital, Yunlin, Taiwan, R.O.C.
- National Tsing Hua University, Hsinchu City, Taiwan, R.O.C.
- National Yang-Ming University Hospital, Yilan, Taiwan, R.O.C.
- Natural Science Foundation of China, P.R. China
- Natural Science Foundation of Jiangsu Province, Jiangsu, P.R. China
- Natural Science Foundation of Shandong Province, Shandong, P.R. China
- Natural Science Foundation of Yangzhou, Yangzhou, P.R. China
- Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
- New Faculty Research Fund, Ajou University School of Medicine, Suwon, Republic of Korea
- New National Excellence Program, Ministry of Human Capacities, Budapest, Hungary
- Nilsson-Ehle's Foundation, Sweden
- Nippon Medical School Hospital, Tokyo, Japan
- Noile-Immune Biotech, Inc., Japan
- Nordic Cancer Union, Reykjavík, Iceland
- Norwegian Radium Hospital Research Foundation, Lysaker, Norway
- Norwegian Radium Hospital, Oslo, Norway
- ODSeasy, asthenis® GmbH, Aschheim, Germany
- Office of Higher Education Commission (OHEC), Thailand
- Oita Cancer Research Foundation, Yufu, Japan
- Oita Red Cross Hospital, Oita, Japan
- Okayama University of Science, Okayama, Japan
- Oklahoma Center for Advancement of Science and Technology, Oklahoma City, OK, U.S.A.
- Oncogenomic Project, Apulia Region, Italy
- Ono Pharmaceutical Co., Ltd, Osaka, Japan
- Opening Research Project of Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Nanjing, P.R. China
- Operational Programme Research and Innovation, European Regional Development Fund (ERDF), Brussels, Belgium
- Osaka Foundation for Promotion of Fundamental Medical Research, Graduate School of Medicine Faculty of Medicine, Osaka University, Suita, Japan
- Osaka Prefecture University, Osaka, Japan
- Paavo Koistinen Foundation, Vuorela, Finland
- Peking University Hospital, Beijing, P.R. China
- Pfizer Pharma GmbH, Berlin, Germany
- Pierre Fabre Pharma GmbH, Freiburg im Breisgau, Germany
- Polish Ministry of Science and Higher Education, Warsaw, Poland
- Polish State Funds for Scientific Research, Warsaw, Poland
- Portuguese NMR (PTNMR) Network, Portugal
- Poznan University of Medical Sciences, Poznan, Poland
- Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED), Tokyo, Japan
- Precision Medicine Special Project of National Key Research and Development Program, P.R. China
- Presbyterian Church in Taiwan, Taipei, Taiwan, R.O.C.
- Princess Takamatsu Cancer Research Fund, Tokyo, Japan
- Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions, Jiangsu, P.R. China

- Program for Professor of Special Appointment (Eastern Scholar), Shanghai Institutions of Higher Learning, Shanghai, P.R. China
- Programa Operacional Competitividade e Internacionalização (POCI), COMPETE2020, Lisboa, Portugal
- Project for Cancer Research and Therapeutic Evolution (P-CREATE), Japan Agency for Medical Research and Development (AMED), Tokyo, Japan
- Project for Development of Innovative Research on Cancer Therapeutics, Japan Agency for Medical Research and Development (AMED), Tokyo, Japan
- Project of Medical Science and Technology Development in Shandong Province, Shandong, P.R. China
- Projects of Medical and Health Technology Development Program in Shandong Province, Shandong, P.R. China
- Province Natural Foundation of Shandong, Shandong, P.R. China
- Quantum and Radiological Science and Technology (QST), National Institute of Radiological Sciences (NIRS), Chiba, Japan
- Radiosensitivity of Individuals and Susceptibility to Cancer induced by ionizing Radiations (RISC-RAD), Community Research and Development Information Service (CORDIS), Seventh Framework Programme, European Commission, Brussels, Belgium
- Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University, Bangkok, Thailand
- Recherches Scientifiques Luxembourg (RSL) Association, Luxembourg
- Regensburger Forschungsfoerderung in der Medizin (ReForM), University of Regensburg, Regensburg, Germany
- Regina Elena National Cancer Institute, Rome, Italy
- Regional Research Board of Northern Norway, Norway
- Research and Development for Innovations Operational Program (RDIOP), ERDF, Brussels, Belgium
- Research Center for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan
- Research Center of the Portuguese Institute of Oncology of Porto, Porto, Portugal
- Research Council of Lithuania, Vilnius, Lithuania
- Research Institute for Veterinary Science, Seoul National University, Seoul, Republic of Korea
- Research Institute of Medical Science, St. Vincent's Hospital, Suwon, Republic of Korea
- Research Institute of Medical Sciences, Chonnam National University, Gwangju, Republic of Korea
- Research Promotion Grant, Shin-Nihon Advanced Medical Research Foundation, Japan
- Richard M Lucas Cancer Foundation, Menlo Park, CA, U.S.A.
- Rizzoli Orthopedic Institute, Palermo, Italy
- Robert Benjamin Ablin Foundation for Cancer Research, Tucson, AZ, U.S.A.
- Robert Bosch Stiftung, Stuttgart, Germany
- Roche S.A.S., Paris, France
- Romanian National Authority for Scientific Research and Innovation (ANCSI), National Research Council (CNCS)-Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI), Romania
- Saitama Medical University International Medical Center, Moroyama, Japan
- Saitama Prefectural University, Koshigaya, Japan
- Saitama Surgical Association, Saitama, Japan
- Sallie Astor Burdine and Delta State University Foundations, Baton Rouge, LA, U.S.A.
- Samyang Corporation, Seoul, Republic of Korea
- Sarcoma Foundation of America (SFA), Damascus, MD, U.S.A.
- Sarcoma SPOREs, NIH, U.S.A.
- Sbarro Health Research Organization (SHRO), Philadelphia, PA, U.S.A.
- SC Laboratory of Musculoskeletal Cell Biology, Rizzoli Orthopedic Institute (IOR), Bologna, Italy
- School of Anti-Aging and Regenerative Medicine, Mae Fah Luang University, Chiang Rai, Thailand
- School of Chinese Medicine, University of Hong Kong, Pokfulam, Hong Kong, P.R. China
- Science and Technology Commission of Beijing, Beijing, P.R. China
- Science and Technology Development Foundation of Yantai, Yantai, P.R. China
- Science and Technology Planning Project of Guangdong Province, Guangdong, P.R. China
- Science and Technology Unit, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
- Science and Technology Unit, Ministry of Health and Welfare, Executive Yuan, Taipei, Taiwan, R.O.C.
- Science for Life Laboratories (SciLifeLab), Uppsala, Sweden
- Science Research Promotion Fund, Promotion and Mutual Aid Corporation for Private Schools of Japan, Japan
- Scientific Research Fund of Beijing Friendship Hospital, Beijing, P.R. China

- Scientific Research Project Commission, Eskisehir Osmangazi University, Eskisehir, Turkey
- Senckenberg's Institute of Pathology, University of Frankfurt, Frankfurt, Germany
- Seoul National University Bundang Hospital Research Fund, Bundang, Republic of Korea
- Seppo Nieminen Fund, Finland
- Ser Cymru Wales, Wales, U.K.
- Setsunan University, Osaka, Japan
- Setsuro Fujii Memorial, Institute of Advanced Medical Sciences, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan
- Shandong Medicine and Health Science Technology Program, Shandong, P.R. China
- Shandong Science and Technology Development Project, Shandong, P.R. China
- Shizuoka Cancer Center Hospital, Shizuoka, Japan
- Show Chwan Memorial Hospital, Changhua City, Taiwan, R.O.C.
- Sigurd and Elsa Goljes Foundation, Sweden
- Slovak Grant Agency, Bratislava, Slovakia
- Small Animal Imaging Facility, University of Pennsylvania, Philadelphia, PA, U.S.A.
- Social Development project of Jiangsu Province, Jiangsu, P.R. China
- Solomon Brothers Medical Technology Corporation for Technical Assistance
- Solutex, Madrid, Spain
- Son Tra Centre Medical Diagnostic Center, Danang, Vietnam
- Soonchunhyang University Research Fund, Asan, Republic of Korea
- South Sweden Breast Cancer Group, Sweden
- Srinakharinwirot University, Bangkok, Thailand
- St. Joseph's Healthcare Foundation, Hamilton, ON, Canada
- Stanford University, Stanford, CA, U.S.A.
- Stellenbosch University, Stellenbosch, South Africa
- Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond, Uppsala, Sweden
- Stiftelsen Tornspiran, Farsta, Sweden
- Stiftung für Pathobiochemie und Molekulare Diagnostik, Bonn, Germany
- Stockholm Cancer Society (Radiumhemsfonderna), Stockholm, Sweden
- Stockholm City Council, Stockholm, Sweden
- Stockholm County Council (ALF project), Stockholm, Sweden
- Support Association, Surgery Department, Santo António Hospital, Porto, Portugal
- Support Center for Advanced Medical Science, Tokushima University Graduate School, Tokushima, Japan
- Support Center for Medical Research and Education, Tokai University, Tokyo, Japan
- Support Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan, Beijing, P.R. China
- Supported Program for the Strategic Research Foundation at Private Universities, Ministry of Education, Culture, Sports, Science and Technology of Japan, Japan
- Suzuken Memorial Foundation, Nagoya, Japan
- Svenska Läkarsällskapet (SLS), Stockholm, Sweden
- Sveriges Kommuner och Landsting (SKL), Stockholm, Sweden
- Swedish Cancer and Allergy Foundation, Stockholm, Sweden
- Swedish Cancer Foundation, Stockholm, Sweden
- Swedish Cancer Society (Cancerfonden), Stockholm, Sweden
- Swedish National Quality Registry of Gynecological Surgery (GynOp Registry), Sweden
- Swedish Research Council (Vetenskapsrådet), Stockholm, Sweden
- Szeged Foundation for Cancer Research, Szeged, Hungary
- Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
- Taipei City Hospital, Taipei, Taiwan, R.O.C.
- Taipei Medical University Hospital, Taipei, Taiwan, R.O.C.
- Taipei Medical University, Taipei, Taiwan, R.O.C.
- Taipei Veterans General Hospital, Yuan-Shan, Taiwan, R.O.C.
- Taiwan Ministry of Health and Welfare (MOHW), Taipei, Taiwan, R.O.C.
- Taiwan Mouse Clinic (TMC), Taipei, Taiwan, R.O.C.
- Takeda Science Foundation, Japan
- Tampere University Hospital, Tampere, Finland
- Taoyuan General Hospital, Ministry of Health and Welfare, Taipei, Taiwan, ROC
- Társadalmi Megújulás Operatív Program (TÁMOP), Hungary
- Télévie Luxembourg, Luxembourg
- Thailand Research Fund, Bangkok, Thailand
- The Scientific and Technological Research Council of Turkey (TUBITAK), Ankara, Turkey
- Tissue Bank, China Medical University, Taichung, Taiwan R.O.C.
- Tokai University Educational System General Research Organization (SO), Tokyo, Japan
- Tokai University Hachioji Hospital, Hachioji, Japan
- Tokai University School of Medicine, Tokyo, Japan

- Tomorrow Medical Foundation, Taiwan, R.O.C.  
 Tottori University, Tottori, Japan  
 Translational Laboratory, Department of Medical Research,  
 Taipei Medical University Hospital, Taipei, Taiwan,  
 R.O.C.  
 TRF Senior Research Scholar Grant, Thailand Research  
 Fund, Bangkok, Thailand  
 Tsukuba University, Tsukuba, Japan
- Umeå University, Umeå, Sweden  
 UMR 1280 Physiologie des Adaptations Nutritionnelles,  
 INRA, Nantes, France  
 Unidade de Investigação de Química Orgânica, Produtos  
 Naturais e Agroalimentares (QOPNA), University of  
 Aveiro, Aveiro, Portugal  
 University of Bonn, Bonn, Austria  
 University of Helsinki, Helsinki, Finland  
 University of Pécs, Pécs, Hungary  
 University of South Florida, Tampa, FL, U.S.A.  
 University of Southern California, Los Angeles, CA, U.S.A.  
 University of the Witwatersrand, Johannesburg, South Africa  
 University of Trás-os-Montes and Alto Douro, Vila Real,  
 Portugal  
 University of Waterloo, Waterloo, ON, Canada  
 Uppsala-Örebro Regional Research Council, Sweden  
 Urology Clinic, Landstuhl Regional Medical Center  
 (LRMC), Landstuhl, Germany
- Varian Medical Systems, Palo Alto, CA, U.S.A.  
 Västerbotten County Council, Sweden  
 Veterans Administration Merit Review Grant, U.S.A.  
 Victor Babes University of Medicine and Pharmacy,  
 Timisoara, Romania
- W. Lutz Stiftung, Nuremberg, Germany  
 Wake Forest Clinical and Translational Science Institute  
 (CTSI), Winston-Salem, NC, U.S.A.  
 Wales Life Science Research Network (NRN), Wales, U.K.  
 Wales National Life Science Research Network (NRN),  
 Cardiff, Wales  
 Walter S. and Lucienne Driskill Foundation, Naperville, IL,  
 U.S.A.  
 Wanfang Hospital Research Program, Taipei, Taiwan,  
 R.O.C.  
 Whittier Foundation, South Pasadena, CA, U.S.A.  
 Working Group for Bone and Soft-Tissue Sarcomas, Japan  
 Wroclaw Centre of Biotechnology, Leading National  
 Research Centre (KNOW), University of Wroclaw,  
 Wroclaw, Poland  
 Wroclaw Centre of Biotechnology, Wroclaw, Poland  
 Wroclaw Medical University, Wroclaw, Poland
- Xuanwu Hospital of Capital Medical University, Beijing,  
 P.R. China
- Yanta Yuhuangding Hospital Initiative Foundation for  
 Young Scientist, Yantai, P.R. China  
 Yantai Municipal Scientific and Technological Development  
 Project, Yantai, P.R. China  
 Yantai Science and Technology Program, Yantai, P.R. China  
 Yonsei University College of Medicine, Seoul, Republic of  
 Korea
- Zhenjiang Science and Technology Development Program,  
 Zhenjiang, P.R. China  
 Zhenjiang Science and Technology Pillar Program,  
 Zhenjiang, P.R. China



## Instructions for Authors 2018

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.)). New York, Plenum Publ Corp., pp 113-136, 1973.

***Nomenclature and Abbreviations.*** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

***Clinical Trials.*** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

***Ethical Policies and Standards.*** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

***Submission of Manuscripts.*** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org)

***Galley Proofs.*** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

### ***Specific information and additional instructions for Authors***

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions for authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.

(Rejection rate (2017): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

**Copyright© 2018** - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

## Reviews